Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance

  • Alegre-Martí, Andrea
  • Jiménez-Panizo, Alba
  • Martínez-Tébar, Adrián
  • Poulard, Coralie
  • Peralta-Moreno, María Nuria
  • Abella, Montserrat
  • Antón, Rosa
  • Chiñas, Marcos
  • Eckhard, Ulrich
  • Piulats, Josep M.
  • Rojas Mendoza, Ana M.
  • Fernández-Recio, Juan
  • Rubio-Martínez, Jaime
  • Romancer, Muriel Le
  • Aytes, Álvaro
  • Fuentes-Prior, Pablo
  • Estébanez-Perpiñá, Eva
Mutations of the androgen receptor (AR) associated with prostate cancer and androgen insensitivity syndrome may profoundly influence its structure, protein interaction network, and binding to chromatin, resulting in altered transcription signatures and drug responses. Current structural information fails to explain the effect of pathological mutations on AR structure–function relationship. Here, we have thoroughly studied the effects of selected mutations that span the complete dimer interface of AR ligand–binding domain (AR-LBD) using x-ray crystallography in combination with in vitro, in silico, and cell-based assays. We show that these variants alter AR-dependent transcription and responses to anti-androgens by inducing a previously undescribed allosteric switch in the AR-LBD that increases exposure of a major methylation target, Arg761. We also corroborate the relevance of residues Arg761 and Tyr764 for AR dimerization and function. Together, our results reveal allosteric coupling of AR dimerization and posttranslational modifications as a disease mechanism with implications for precision medicine., E.E.-P. thanks G. E. Carretero and A. T. Hagler for sponsorships, CaixaImpulse 2018-00018 La Caixa, and 2018-Llavor with 2017SGR1089 (to P.F.-P.; Generalitat de Catalunya). E.E.-P. thanks 2021SGR01433, BFU-Retos2017-86906-R, PDC2021-121688-100, and SAF2017-71878-REDT (Red Nacional de Receptores Nucleares, NurCaMeIn) with SAF2019-REDT-Uroncomol (to A.A.; Red Nacional de Mecanismos Moleculares del Cáncer Urológico, Uroncomol), RTI2018-101500-B-I00 (to P.F.-P.), PID2019-110167RB-I00/AEI/10.13039/501100011033 (to J.F.-R.), and RTI2018-096735-B-100 (to A.R.; MINECO). A.A. thanks PI19/00342 and CPII20/00024 (Instituto de Salud Carlos III), W81XWH-18-1-0193 (Department of Defense), and 2017SGR448 (Generalitat de Catalunya). U.E. acknowledges support from the Spanish Ministry of Science and Innovation (RYC2020-029773-I and PID2021-128682OA-I00). M.N.P.-M. thanks Predocs-UB2020 5760700. J.R.-M. thanks grants 2021SGR00350 and CEX2021-001202-M. C.P. and M.L.R. were supported by financial support from ITMO Cancer of Aviesan within the framework of the 2021-2030 Cancer Control Strategy, on funds administered by Inserm., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001202-M).